Amgen adds former Yum! Brands CEO David Gibbs to board
Gibbs joins Amgen's Audit and Compensation and Management Development committees effective immediately, expanding the board to 13 directors.
Amgen announced on October 26, 2026 that it appointed David W. Gibbs to its Board of Directors, effective immediately.1 Gibbs will serve on the Board's Audit Committee and Compensation and Management Development Committee.1
Gibbs most recently led Yum! Brands. According to the filing, he served as Chief Executive Officer of Yum! Brands, Inc. from 2020 to September 2025 and as a director of Yum! Brands from 2019 to September 2025.1 Since October 2025, Gibbs has served as an advisor to Yum! Brands.1 Earlier in his career, he served as President and Chief Operating Officer of Yum! Brands from August 2019 to December 2019; President, Chief Operating Officer and Chief Financial Officer from January 2019 to August 2019; and President and Chief Financial Officer from 2016 to 2018.1 He also held roles including Chief Executive Officer of the Pizza Hut Division from 2015 to 2016, President of Pizza Hut U.S. in 2014, and President and Chief Financial Officer of Yum! Restaurants International, Inc. from 2012 to 2013.1
Gibbs currently holds other board seats. The filing states he has served as a director of Under Armour, Inc. since 2021 and is Chair of its Human Capital and Compensation Committee1, and has served as a director of PepsiCo, Inc. since 2026 and is a member of its Audit Committee.1
Amgen said there are no transactions between Gibbs, or his immediate family, and the company that would be reportable under Item 404(a) of Regulation S-K, and no arrangement or understanding exists regarding his appointment.1
For compensation, Gibbs will receive a pro-rated annual cash retainer of $115,000 and committee meeting retainers of $12,500 through December 31, 2026, according to the filing. Under the company's director equity incentive program, non-employee directors receive an annual grant of restricted stock units valued at $220,000, and Gibbs will receive a pro-rated 7/12 portion two business days after Amgen's 2026 third quarter earnings release.1
Following the appointment, the Board will be composed of 13 directors, 12 of whom are independent.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.